Hormonal development therapy (HDT) in hypogonadism in long-term view.

Area of Science:

• Reproductive Endocrinology
• Pediatric Endocrinology
• Hormone Therapy

Background:

• Estrogen deficiency in girls with hypogonadism requires treatment to ensure proper sexual development.
• Hormonal Development Therapy (HDT) is distinct from menopausal Hormone Replacement Therapy (HRT) in its goals and application.
• Specific HDT is vital for growth, reproductive function, bone and lipid metabolism, and immune, nervous, and cardiovascular systems in hypogonadal girls.

Purpose of the Study:

• To define and differentiate Hormonal Development Therapy (HDT) for hypogonadal girls from menopausal HRT.
• To highlight the essential role of HDT in supporting comprehensive development in hypogonadal girls.
• To discuss indications, protocols, and long-term considerations for HDT in puberty.

Main Methods:

• Review of historical treatment approaches analogous to menopausal HRT.
• Distinguishing the unique objectives and methodologies of HDT for hypogonadism.
• Analysis of international consensus and existing literature on HDT protocols.

Main Results:

• HDT is essential for inducing and supporting sexual development in hypogonadal girls.
• HDT addresses critical aspects of physical and systemic development beyond mere replacement.
• HDT initiation is recommended at the onset of expected puberty, particularly in cases of absolute estrogen deficiency.

Conclusions:

• HDT is a specialized therapy for hypogonadal girls, distinct from menopausal HRT.
• Lifelong HDT is suggested for sustained female development and function, though long-term risks require further study.
• Further research is needed to establish precise consensus on risks and side effects of continuous HDT.